共 15 条
[1]
Kivela T., The epidemiological challenge of the most frequent eye cancer: retinoblastoma, an issue of birth and death, Br J Ophthalmol, 93, pp. 1129-1131, (2009)
[2]
Shields C.L., Meadows A.T., Leahey A.M., Shields J.A., Continuing challenges in the management of retinoblastoma with chemotherapy, Retina, 24, pp. 849-862, (2004)
[3]
Shields C.L., Douglass A.M., Beggache M., Say E.A., Shields J.A., Intravitreous chemotherapy for active vitreous seeding from retinoblastoma: outcomes after 192 consecutive injections. The 2015 Howard Naquin Lecture, Retina, 36, pp. 1184-1190, (2016)
[4]
Abramson D.H., Daniels A.B., Marr B.P., Et al., Intra-arterial chemotherapy (ophthalmic artery chemosurgery) for group D retinoblastoma, PLoS One, 11, (2016)
[5]
Fabian I.D., Naeem Z., Stacey A.W., Et al., Long-term visual acuity, strabismus, and nystagmus outcomes following multimodality treatment in group D retinoblastoma eyes, Am J Ophthalmol, 179, pp. 137-144, (2017)
[6]
Linn Murphree A., Intraocular retinoblastoma: the case for a new group classification, Ophthalmol Clin North Am, 18, pp. 41-53, (2005)
[7]
Mallipatna A.C., Gallie B.L., Chevez-Barrios P., Et al., Retinoblastoma, AJCC Cancer Staging Manual, pp. 819-831, (2017)
[8]
Muen W.J., Kingston J.E., Robertson F., Brew S., Sagoo M.S., Reddy M.A., Efficacy and complications of super-selective intra-ophthalmic artery melphalan for the treatment of refractory retinoblastoma, Ophthalmology, 119, pp. 611-616, (2012)
[9]
The ischemic optic neuropathy decompression trial (IONDT): design and methods, Control Clin Trials, 19, pp. 276-296, (1998)
[10]
Watts P., Westall C., Colpa L., Et al., Visual results in children treated for macular retinoblastoma, Eye (Lond), 16, pp. 75-80, (2002)